Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hemodynamic Response of Rifaximin plus Non-selective β-blocker versus Non-selective β-blocker Monotherapy in Cirrhotic Patients with Esophageal Varices
KCT0000788Phase 3Not yet recruiting
- Sponsor
- Hanwha Solutions Chemical Division
- Start
- Jul 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of rifaximin in Cirrhosis, esophageal varices, sponsored by Hanwha Solutions Chemical Division. Planned start Jul 2013; status: not yet recruiting.
02
Drugs
rifaximin
03
Conditions
Cirrhosisesophageal varices
Beyond the preview
Go deeper on KCT0000788.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0000788.